FDA accepts all three formats, the PADER/PAER, PSUR, and PBRER, to fulfill the postmarketing periodic safety reporting requirements under §§ 314.80(c)(2) and 600.80(c)(2). Each format …
Providing Postmarket Periodic Safety Reports in the ICH …
2024年12月19日 · This guidance describes the conditions under which applicants can use an alternative reporting format, the International Council for Harmonisation (ICH)3 E2C (R2) …
Postmarketing Safety Reporting for Human Drug and …
This guidance is intended to assist applicants and other responsible parties in fulfilling the FDA=s existing postmarketing safety reporting requirements for human marketed drug and biological...
Providing Postmarketing Periodic Safety Reports in the …
2016年11月29日 · FDA has routinely granted waivers under 21 CFR 314.90(b) and 600.90(b) permitting applicants to submit an internationally harmonized Periodic Safety Update Report …
SUSAR和DSUR，以及上市后PSUR和PBRER梳理对比 / 药物警戒活 …
为规范药品上市许可持有人和获准开展药物临床试验的药品注册申请人依法承担药物警戒主体责任，2020年12月3日，国家药品监督管理局发布《药物警戒质量管理规范（征求意见稿）》，向 …
52 (E2C guideline), which established the PSUR as a harmonized format for postmarket periodic 53 safety reporting for approved drugs and biologic products, and described the format, …
根据《药品定期安全性更新报告撰写规范》要求，制药企业应以取得药品批准证明文件的日期（cbd）为起点计，撰写psur。 如果公司统一的psur撰写频率高于我国现行法规要求，依据公 …
【专业解读】MDR下PSUR报告揭秘 - 知乎 - 知乎专栏
PSUR，即Periodic Safety Update Report，是根据MDR法规Article 86引入的一项要求。 它要求制造商对IIa类、IIb类和III类医疗器械进行更一致、标准化和系统化的上市后监测 (PMS)数据审查 …
Template: Periodic Safety Update Report – FDA Today
Summarize the key findings of the current PSUR and provide essential background information to make the PSUR self-contained. The executive summary should include a decisive statement …
Search | FDA - U.S. Food and Drug Administration
Safety Data Management: Periodic Safety Update Report (PSUR), (4) FDA guidance for industry on Postmarketing Adverse …